This indicates that the conjugation of the Pt(IV) pharmacophore with the HDAC inhibitor (VPA) produces a synergetic effect, conferring the resulting complex, cisPt(VPA)2, higher cytotoxicity against the cancer cells than the combination of free cisplatin and VPA. The gene discussed is HDAC9; the disease is cancer.